Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):297-304. doi: 10.1016/j.ijrobp.2010.02.017. Epub 2010 Jun 18.
For 23 patients, an off-line positron emission tomography scan and a computed tomography scan after proton radiotherapy was performed at the Massachusetts General Hospital to assess in vivo treatment verification. A well-balanced population of patients was investigated to assess the effect of the tumor location on the accuracy of the technique.
Range verification was achieved by comparing the measured positron emission tomography activity distributions with the corresponding Monte Carlo-simulated distributions. Observed differences in the distal end of the activity distributions were analyzed as potential indicators for the range differences between the actual delivered and planned dose.
The average spatial agreement between the measured and simulated activity distribution was within ±3 mm, and the corresponding average absolute agreement was within ±45% (derived from gamma index analysis). The mean absolute range deviation at 93 randomly chosen positions in 17 treatment fields delivered to 11 patients was 3.6 mm. Characteristic differences in the agreement of the measured and simulated activity distribution for the different tumor/target sites were found. This resulted from the different effect of factors such as biologic washout effects, motion, or limitations in the Monte Carlo-simulated activity patterns.
We found that intracranial and cervical spine patients can greatly benefit from off-line positron emission tomography and computed tomography range verification. However, for the successful application of the method to patients with abdominopelvic tumors, major technological and methodologic improvements are needed. Among the intracranial and cervical spine target sites, patients with arteriovenous malformations or metal implants represent groups that could especially benefit from the approach.
在马萨诸塞州综合医院,对 23 例接受质子放射治疗的患者进行了离线正电子发射断层扫描和计算机断层扫描,以评估体内治疗验证。通过调查具有良好平衡特征的患者群体,评估肿瘤位置对技术准确性的影响。
通过比较测量的正电子发射断层扫描活性分布与相应的蒙特卡罗模拟分布来实现范围验证。分析活性分布的远端观察到的差异,作为实际递送和计划剂量之间的范围差异的潜在指标。
测量和模拟的活性分布之间的平均空间一致性在±3mm 以内,相应的平均绝对一致性在±45%以内(源自伽马指数分析)。在 11 名患者的 17 个治疗野中随机选择的 93 个位置的平均绝对范围偏差为 3.6mm。对于不同的肿瘤/靶区,测量和模拟的活性分布之间的一致性存在特征差异。这是由于生物学清除效应、运动或蒙特卡罗模拟的活性模式的限制等因素的不同影响所致。
我们发现,颅内和颈椎患者可以从离线正电子发射断层扫描和计算机断层扫描的范围验证中大大受益。然而,要将该方法成功应用于腹盆部肿瘤患者,需要进行重大的技术和方法改进。在颅内和颈椎靶区中,动静脉畸形或金属植入物的患者是特别受益于该方法的群体。